• +1-646-491-9876
    • +91-20-67278686

    Search

    Gastrointestinal Stromal Tumor-Pipeline Review H1 2017

    Gastrointestinal Stromal Tumor-Pipeline Review H1 2017

    • Report Code ID: RW0001834409
    • Category Pharmaceuticals
    • No. of Pages 258
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2017, provides an overview of the Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline landscape.

    Gastrointestinal stromal tumors (GISTs) are tumors, which occur in the gastrointestinal tract. Gastrointestinal stromal tumors belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea and vomiting, vomiting blood or having blood in the stool and fatigue due to anemia (low red blood cell counts) . Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy and chemotherapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 16, 11, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

    Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST) (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Publisher Report Coverage 7
    Gastrointestinal Stromal Tumor (GIST) - Overview 8
    Gastrointestinal Stromal Tumor (GIST) - Therapeutics Development 9
    Pipeline Overview 9
    Pipeline by Companies 10
    Pipeline by Universities/Institutes 13
    Products under Development by Companies 14
    Products under Development by Universities/Institutes 16
    Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment 17
    Assessment by Target 17
    Assessment by Mechanism of Action 20
    Assessment by Route of Administration 23
    Assessment by Molecule Type 25
    Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development 27
    AB Science SA 27
    Advanced Accelerator Applications SA 27
    Advenchen Laboratories LLC 28
    Ariad Pharmaceuticals Inc 28
    Arog Pharmaceuticals Inc 29
    ArQule Inc 29
    Array BioPharma Inc 30
    Astex Pharmaceuticals Inc 30
    Blueprint Medicines Corp 31
    Boston Biomedical Inc 31
    Calithera Biosciences Inc 32
    Celldex Therapeutics Inc 32
    Chipscreen Biosciences Ltd 33
    CytRx Corp 33
    Deciphera Pharmaceuticals LLC 34
    Exelixis Inc 34
    F. Hoffmann-La Roche Ltd 35
    Hanmi Pharmaceuticals Co Ltd 35
    Horizon Pharma Plc 36
    Immunicum AB 36
    Jiangsu Hengrui Medicine Co Ltd 37
    Natco Pharma Ltd 37
    Nerviano Medical Sciences Srl 38
    Novartis AG 38
    Omeros Corp 39
    Pharma Mar SA 39
    Plexxikon Inc 40
    Rhizen Pharmaceuticals SA 40
    Taiho Pharmaceutical Co Ltd 41
    Gastrointestinal Stromal Tumor (GIST) - Drug Profiles 42
    aldoxorubicin hydrochloride - Drug Profile 42
    amcasertib - Drug Profile 59
    apatinib - Drug Profile 62
    ARQ-092 - Drug Profile 67
    binimetinib - Drug Profile 70
    BLU-285 - Drug Profile 79
    buparlisib hydrochloride - Drug Profile 83
    cabozantinib s-malate - Drug Profile 89
    CB-839 - Drug Profile 108
    CDX-0158 - Drug Profile 116
    CHMFLKIT-110 - Drug Profile 119
    crenolanib besylate - Drug Profile 120
    CS-2164 - Drug Profile 124
    dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 125
    DCC-2618 - Drug Profile 133
    everolimus - Drug Profile 135
    HM-95573 - Drug Profile 147
    interferon gamma-1b - Drug Profile 149
    Intuvax - Drug Profile 154
    masitinib - Drug Profile 160
    nilotinib - Drug Profile 176
    NMSP-088 - Drug Profile 182
    NRCAN-019 - Drug Profile 183
    onalespib - Drug Profile 185
    Peptide to Antagonize GRPR for Oncology - Drug Profile 189
    pexidartinib - Drug Profile 190
    PLX-9486 - Drug Profile 195
    PM-184 - Drug Profile 196
    ponatinib hydrochloride - Drug Profile 198
    SF-1126 - Drug Profile 214
    SHR-1020 - Drug Profile 216
    Small Molecule to Antagonize GPR20 for Acute Myeloid Leukemia and Gastro-Intestinal Stromal Tumors - Drug Profile 218
    Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - Drug Profile 219
    TAS-116 - Drug Profile 220
    TGR-1202 - Drug Profile 221
    vemurafenib - Drug Profile 230
    WBZ-4 - Drug Profile 237
    Gastrointestinal Stromal Tumor (GIST) - Dormant Projects 238
    Gastrointestinal Stromal Tumor (GIST) - Discontinued Products 239
    Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones 240
    Featured News & Press Releases 240
    Appendix 255
    Methodology 255
    Coverage 255
    Secondary Research 255
    Primary Research 255
    Expert Panel Validation 255
    Contact Us 255
    Disclaimer 256

    List of Tables

    Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advanced Accelerator Applications SA, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advenchen Laboratories LLC, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals Inc, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Arog Pharmaceuticals Inc, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by ArQule Inc, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Array BioPharma Inc, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals Inc, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines Corp, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Boston Biomedical Inc, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Calithera Biosciences Inc, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Celldex Therapeutics Inc, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by CytRx Corp, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Exelixis Inc, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Horizon Pharma Plc, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Immunicum AB, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Natco Pharma Ltd, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Nerviano Medical Sciences Srl, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Omeros Corp, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Pharma Mar SA, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Plexxikon Inc, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Rhizen Pharmaceuticals SA, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H1 2017
    Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AB Science SA
    Advanced Accelerator Applications SA
    Advenchen Laboratories LLC
    Ariad Pharmaceuticals Inc
    Arog Pharmaceuticals Inc
    ArQule Inc
    Array BioPharma Inc
    Astex Pharmaceuticals Inc
    Blueprint Medicines Corp
    Boston Biomedical Inc
    Calithera Biosciences Inc
    Celldex Therapeutics Inc
    Chipscreen Biosciences Ltd
    CytRx Corp
    Deciphera Pharmaceuticals LLC
    Exelixis Inc
    F. Hoffmann-La Roche Ltd
    Hanmi Pharmaceuticals Co Ltd
    Horizon Pharma Plc
    Immunicum AB
    Jiangsu Hengrui Medicine Co Ltd
    Natco Pharma Ltd
    Nerviano Medical Sciences Srl
    Novartis AG
    Omeros Corp
    Pharma Mar SA
    Plexxikon Inc
    Rhizen Pharmaceuticals SA
    Taiho Pharmaceutical Co Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//gastrointestinal-stromal-tumor-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//gastrointestinal-stromal-tumor-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//gastrointestinal-stromal-tumor-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments